Literature DB >> 23685330

Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings.

Celia J A Morgan1, Ravi K Das, Alyssa Joye, H Valerie Curran, Sunjeev K Kamboj.   

Abstract

The role of the endocannabinoid system in nicotine addiction is being increasingly acknowledged. We conducted a pilot, randomised double blind placebo controlled study set out to assess the impact of the ad-hoc use of cannabidiol (CBD) in smokers who wished to stop smoking. 24 smokers were randomised to receive an inhaler of CBD (n=12) or placebo (n=12) for one week, they were instructed to use the inhaler when they felt the urge to smoke. Over the treatment week, placebo treated smokers showed no differences in number of cigarettes smoked. In contrast, those treated with CBD significantly reduced the number of cigarettes smoked by ~40% during treatment. Results also indicated some maintenance of this effect at follow-up. These preliminary data, combined with the strong preclinical rationale for use of this compound, suggest CBD to be a potential treatment for nicotine addiction that warrants further exploration.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23685330     DOI: 10.1016/j.addbeh.2013.03.011

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  46 in total

Review 1.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

2.  Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation.

Authors:  Jason D Robinson; Paul M Cinciripini; Maher Karam-Hage; Henri-Jean Aubin; Lowell C Dale; Raymond Niaura; Robert M Anthenelli
Journal:  Addict Biol       Date:  2017-04-21       Impact factor: 4.280

3.  Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental Illness?

Authors:  Philip G Tibbo; Kyle A McKee; Jeffrey H Meyer; Candice E Crocker; Katherine J Aitchison; Raymond W Lam; David N Crockford
Journal:  Can J Psychiatry       Date:  2020-09-11       Impact factor: 4.356

Review 4.  Terpenes and lipids of the endocannabinoid and transient-receptor-potential-channel biosignaling systems.

Authors:  David R Janero; Alexandros Makriyannis
Journal:  ACS Chem Neurosci       Date:  2014-06-05       Impact factor: 4.418

Review 5.  Role of cannabis in cardiovascular disorders.

Authors:  Hemant Goyal; Hamza H Awad; Jalal K Ghali
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

6.  Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle.

Authors:  Gustavo Gonzalez-Cuevas; Remi Martin-Fardon; Tony M Kerr; David G Stouffer; Loren H Parsons; Dana C Hammell; Stan L Banks; Audra L Stinchcomb; Friedbert Weiss
Journal:  Neuropsychopharmacology       Date:  2018-03-22       Impact factor: 7.853

Review 7.  Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.

Authors:  G M Mandolini; M Lazzaretti; A Pigoni; L Oldani; G Delvecchio; P Brambilla
Journal:  Epidemiol Psychiatr Sci       Date:  2018-05-23       Impact factor: 6.892

8.  Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.

Authors:  Tom P Freeman; Chandni Hindocha; Gianluca Baio; Natacha D C Shaban; Emily M Thomas; Danica Astbury; Abigail M Freeman; Rachel Lees; Sam Craft; Paul D Morrison; Michael A P Bloomfield; Dominic O'Ryan; Jane Kinghorn; Celia J A Morgan; Ali Mofeez; H Valerie Curran
Journal:  Lancet Psychiatry       Date:  2020-07-28       Impact factor: 27.083

Review 9.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

Review 10.  Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.

Authors:  Dennis J Sholler; Marilyn A Huestis; Benjamin Amendolara; Ryan Vandrey; Ziva D Cooper
Journal:  Pharmacol Biochem Behav       Date:  2020-10-18       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.